Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new window
investorenquiries@pharmaust.com+61 8 9202 6814
PharmAust (PAA)
PharmAust (PAA)
  • HOME
  • ABOUT
    • Company Overview
    • PharmAust Management
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
    • Motor Neuron Disease Trial
  • INVESTOR CENTRE
    • PhamAust AGM 2022
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT
  • HOME
  • ABOUT
    • Company Overview
    • PharmAust Management
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
    • Motor Neuron Disease Trial
  • INVESTOR CENTRE
    • PhamAust AGM 2022
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT

Author Archives: PharmAust

PharmAust doses first patient in Phase 1/2 trial of monepantel treating Motor Neurone Disease

News & Announcements 2022By PharmAustOctober 3, 2022

PharmAust doses first patient in Phase 1/2 trial of monepantel treating Motor Neurone Disease (External link)

PharmAust (ASX:PAA) doses first patient in MND trial

News & Announcements 2022By PharmAustOctober 3, 2022

PharmAust (ASX:PAA) doses first patient in MND trial (External ink)

First Patient Dosed in MND Phase 1/2 Trial

News & Announcements 2022By PharmAustOctober 3, 2022

First Patient Dosed in MND Phase 1-2 Trial

Top 20 Shareholders

Top 20 ShareholdersBy PharmAustSeptember 30, 2022

Top_Holders_Report (1)

Notice of Annual General Meeting 2022

News & Announcements 2022By PharmAustSeptember 30, 2022

Notice of AGM 2022

PharmAust says MPL can double the life expectancy of dogs with cancer; US trials to begin

News & Announcements 2022By PharmAustAugust 18, 2022

PharmAust says MPL can double the life expectancy of dogs with cancer; US trials to begin (External Link)

Update on PharmAust Canine Cancer Trials

News & Announcements 2022By PharmAustAugust 17, 2022

Update on PharmAust Canine Cancer Trials

PharmAust’s MPL trials show doubled life expectancy for dogs with cancer

News & Announcements 2022By PharmAustAugust 17, 2022

PharmAust’s MPL trials show doubled life expectancy for dogs with cancer (External Link)

PharmAust (ASX:PAA) sees “significant progress” in dog cancer trials

News & Announcements 2022By PharmAustAugust 17, 2022

PharmAust (ASX:PAA) sees “significant progress” in dog cancer trials (External Link)

Top 20 Shareholders

Top 20 ShareholdersBy PharmAustAugust 1, 2022

Top_Holders_Report (4)

←12345…
67891011121314151617181920212223242526272829303132333435363738394041424344454647
48→
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER


Facebook
Facebook
fb-share-icon
Twitter
YouTube
TWITTER

PharmAust Follow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust
pharmaust PharmAust @pharmaust ·
13h

PharmAust (ASX:PAA) completes enrolment of second patient cohort in MND/ALS trial https://themarketherald.com.au/pharmaust-asxpaa-completes-enrolment-of-second-patient-cohort-in-mnd-als-trial-2023-03-30/ via @themarketherald

Reply on Twitter 1641338317286543360 Retweet on Twitter 1641338317286543360 2 Like on Twitter 1641338317286543360 11 Twitter 1641338317286543360
pharmaust PharmAust @pharmaust ·
18h

PharmAust completes patient enrolment for MPL trial with sights on US$3.6 billion Motor Neurone Disease market

https://stockhead.com.au/health/pharmaust-completes-patient-enrolment-for-mpl-trial-with-sights-on-us3-6-billion-motor-neurone-disease-market/

Reply on Twitter 1641272193236758529 Retweet on Twitter 1641272193236758529 4 Like on Twitter 1641272193236758529 14 Twitter 1641272193236758529
pharmaust PharmAust @pharmaust ·
20h

Pandemic Pet Adoptions Propel Rise of a $500 Billion Global Market
Via ⁦@Bloomberg⁩ https://www.bloomberg.com/news/articles/2023-03-24/pet-industry-outlook-is-strong-despite-rising-costs-of-food-vet-care

Reply on Twitter 1641241590726561792 Retweet on Twitter 1641241590726561792 3 Like on Twitter 1641241590726561792 8 Twitter 1641241590726561792
Load More
Copyright © 2023 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top